AR090835A1 - Derivados de quinazolindiona - Google Patents
Derivados de quinazolindionaInfo
- Publication number
- AR090835A1 AR090835A1 ARP130101381A ARP130101381A AR090835A1 AR 090835 A1 AR090835 A1 AR 090835A1 AR P130101381 A ARP130101381 A AR P130101381A AR P130101381 A ARP130101381 A AR P130101381A AR 090835 A1 AR090835 A1 AR 090835A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl group
- alkyl
- members
- groups
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 22
- 125000005843 halogen group Chemical group 0.000 abstract 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 12
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000000623 heterocyclic group Chemical group 0.000 abstract 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 7
- 125000003277 amino group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 abstract 1
- 108010049959 Discoidins Proteins 0.000 abstract 1
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 abstract 1
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- -1 amino, hydroxyl Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 abstract 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Inhibidores de DDR₁, receptor de dominio discoidina 1 (receptor tirosina quinasa), útiles para tratar cáncer, metástasis, fibrosis y/o inflamación. Reivindicación 1: Un compuesto caracterizado porque está representado por la fórmula general (1), o una sal aceptable farmacéuticamente del mismo, donde A representa la fórmula (2) ó (3); Q representa CH₂ o NH; A¹ representa N o CR¹; R¹ representa un átomo de hidrógeno, grupo alquilo C₁₋₃, grupo alcoxi C₁₋₃, átomo de halógeno, o grupo ciano, donde el grupo alquilo C₁₋₃ o grupo alcoxi C₁₋₃ puede estar sustituido con entre 1 y 5 átomos de halógeno, donde si A² y/o A³ es N, R¹ puede ser un átomo de hidrógeno; A² representa N o CR²; R² representa un átomo de hidrógeno, grupo alquilo C₁₋₃, grupo alcoxi C₁₋₃, o átomo de halógeno; A³ representa N o CR³; R³ representa un átomo de hidrógeno, grupo alquilo C₁₋₆, grupo alcoxi C₁₋₆, o átomo de halógeno; R⁴ representa un grupo alquil C₁₋₆sulfonilo, grupo alquil C₁₋₆sulfanilo, grupo alquil C₁₋₆sulfinilo, grupo cicloalquil C₃₋₈sulfonilo, grupo cicloalquil C₃₋₈sulfanilo, grupo cicloalquil C₃₋₈sulfinilo, grupo aril C₆₋₁₀sulfonilo, grupo aril C₆₋₁₀sulfanilo, o grupo aril C₆₋₁₀sulfinilo; R⁵ representa un átomo de halógeno, grupo alquilo C₁₋₆, grupo alcoxi C₁₋₆, grupo alquenilo C₂₋₆, grupo ciano, grupo nitro, grupo cicloalquilo C₃₋₈, anillo aromático de entre 4 y 10 miembros, heterociclo aromático de entre 4 y 10 miembros, heterociclo de entre 3 y 12 miembros, o grupo alquil C₁₋₆sulfanilo, donde el grupo alquilo C₁₋₆, grupo alcoxi C₁₋₆, grupo alquenilo C₂₋₆, o grupo alquil C₁₋₆sulfanilo puede estar sustituido con entre 1 y 5 átomos de halógeno; R⁶ representa un átomo de hidrógeno, un grupo alquilo C₁₋₆, grupo alquenilo C₂₋₆, átomo de halógeno, grupo formilo, [1,3]dioxolano, o un grupo representado por la fórmula (i): ·--X--Y--Z, donde el grupo alquilo C₁₋₆ o grupo alquenilo C₂₋₆ puede estar sustituido con entre 1 y 5 grupos amino, hidroxilo, y/o OSO₂CH₃, donde en la fórmula (i), X representa -(CH₂)ₙ-, -NH-, o -O-; Y representa un anillo aromático de entre 4 y 10 miembros, heterociclo de entre 3 y 12 miembros, o heterociclo aromático de entre 4 y 10 miembros, donde el anillo aromático de entre 4 y 10 miembros, heterociclo de entre 3 y 12 miembros, y heterociclo aromático de entre 4 y 10 miembros puede estar sustituido con entre 1 y 5 átomos de halógeno y/o grupos alquilo C₁₋₃; Z representa un átomo de hidrógeno, un grupo alquilo C₁₋₆, un grupo alquinilo C₂₋₆, un grupo cicloalquilo C₃₋₈, -(CH₂)ₘNRᵃRᵇ, NHCO(CH₂)ₘRᶜ, -(CH₂)ₘNHCORᶜ, NH(CH₂)ₘCORᶜ, (CH₂)ₘN(CH₃)CORᶜ, (CH₂)ₘORᵈ, -(CH₂)ₘCORᵉ, -(CH₂)ₘCOORᵉ, (CH₂)ₘNHSO₂Rᶠ, (CH₂)ₘSO₂Rᶠ, -(CH₂)ₘCONRᵍRʰ, un anillo aromático de entre 4 y 10 miembros, heterociclo aromático de entre 4 y 10 miembros, o un heterociclo de entre 3 y 12 miembros, donde el grupo alquilo C₁₋₆ puede estar sustituido con entre 1 y 5 átomos de halógeno, grupos hidroxilo, y/o grupos ciano; y el heterociclo de entre 3 y 12 miembros y heterociclo aromático de entre 4 y 10 miembros puede estar sustituido con entre 1 y 5 átomos de halógeno, grupos alquilo C₁₋₃, y/o grupos oxo; n representa 0, 1, 2 ó 3; m representa 0, 1, 2, o 3; Rᵃ y Rᵇ son idénticos o diferentes, representando cada uno un átomo de hidrógeno, grupo alquilo C₁₋₆, grupo alquinilo C₂₋₆, heterociclo de entre 3 y 12 miembros, heterociclo aromático de entre 4 y 10 miembros, o -SO₂CH₃, donde el grupo alquilo C₁₋₆ puede estar sustituido con entre 1 y 5 átomos de halógeno, grupos amino, grupos hidroxilo, y/o grupos ciano; Rᶜ representa un grupo alquilo C₁₋₆, grupo alcoxi C₁₋₆, grupo cicloalquilo C₃₋₈, grupo amino, o heterociclo de entre 3 y 12 miembros, donde el grupo alquilo C₁₋₆ puede estar sustituido con entre 1 y 3 grupos amino, grupos mono-alquil C₁₋₆amino, grupos di-alquil C₁₋₆amino, y/o heterociclos de entre 3 y 12 miembros; Rᵈ representa un átomo de hidrógeno, grupo alquilo C₁₋₆, o grupo alquinilo C₂₋₆, donde el grupo alquilo C₁₋₆ puede estar sustituido con entre 1 y 5 grupos alcoxi C₁₋₆ y/o grupos amino; Rᵉ representa un átomo de hidrógeno o grupo alquilo C₁₋₆, donde el grupo alquilo C₁₋₆ puede estar sustituido con un grupo amino; Rᶠ representa un grupo alquilo C₁₋₆, un grupo amino, un grupo mono-alquil C₁₋₆amino, o un grupo di-alquil C₁₋₆amino; y Rᵍ y Rʰ son idénticos o diferentes, representando cada uno un átomo de hidrógeno, grupo alquilo C₁₋₆, o heterociclo de entre 3 y 12 miembros, donde el grupo alquilo C₁₋₆ puede estar sustituido con entre 1 y 3 grupos amino, grupos mono-alquil C₁₋₆amino, y/o grupos di-alquil C₁₋₆amino; y R⁷ representa un átomo de hidrógeno, átomo de halógeno, grupo alquilo C₁₋₆, grupo alquenilo C₂₋₆, grupo alcoxi C₁₋₆, grupo ciano, o un grupo representado por la fórmula (ii) ·--X²--Y²--Z², donde el grupo alquilo C₁₋₆ puede estar sustituido con entre 1 y 5 átomos de halógeno, fórmula (ii) donde X² representa -(CH₂)ₚ-; Y² representa un heterociclo de entre 3 y 12 miembros o heterociclo aromático de entre 4 y 10 miembros; Z² representa un átomo de hidrógeno, grupo alquilo C₁₋₆, grupo alquenilo C₂₋₆, grupo alcoxi C₁₋₆, grupo cicloalquilo C₃₋₇, grupo ciano, o COORⁱ; p representa 0, 1 ó 2; y Rⁱ representa un grupo alquilo C₁₋₆.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012098954 | 2012-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090835A1 true AR090835A1 (es) | 2014-12-10 |
Family
ID=49483161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101381A AR090835A1 (es) | 2012-04-24 | 2013-04-24 | Derivados de quinazolindiona |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9567304B2 (es) |
| EP (1) | EP2842946B1 (es) |
| JP (1) | JP6130828B2 (es) |
| KR (1) | KR20150003849A (es) |
| CN (1) | CN104379568A (es) |
| AR (1) | AR090835A1 (es) |
| AU (1) | AU2013253541A1 (es) |
| BR (1) | BR112014026305A2 (es) |
| CA (1) | CA2871453A1 (es) |
| HK (1) | HK1203943A1 (es) |
| MX (1) | MX2014012992A (es) |
| RU (1) | RU2014146993A (es) |
| SG (1) | SG11201406860SA (es) |
| TW (1) | TW201348213A (es) |
| WO (1) | WO2013161853A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2871237A1 (en) | 2012-04-24 | 2013-10-31 | Chugai Seiyaku Kabushiki Kaisha | Benzamide derivative |
| US10005739B2 (en) | 2013-10-23 | 2018-06-26 | Chugai Seiyaku Kabushiki Kaisha | Quinazolinone and isoquinolinone derivative |
| WO2016039408A1 (ja) * | 2014-09-11 | 2016-03-17 | 武田薬品工業株式会社 | 複素環化合物 |
| BR112018002127A2 (pt) | 2015-08-31 | 2018-09-11 | Toray Industries, Inc. | derivado de ureia, e, inibidor de receptor de domínio de discoidina 1 |
| HK1248208A1 (zh) | 2015-08-31 | 2018-10-12 | 东丽株式会社 | 尿素衍生物和其用途 |
| WO2018138050A1 (de) | 2017-01-26 | 2018-08-02 | Bayer Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| PY2012000A (es) | 2019-02-26 | 2023-07-25 | Bayer Ag | Derivados de heterociclos bicíclicos fusionados como pesticidas |
| CN110218193A (zh) * | 2019-07-08 | 2019-09-10 | 山东大学 | 3-羟基喹唑啉-2,4(1h,3h)-二酮类衍生物及其制备方法与应用 |
| CN112608282B (zh) * | 2019-12-20 | 2022-07-26 | 山东先达农化股份有限公司 | 一种含喹唑啉二酮和n-o结构的化合物及其制备方法和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK570987A (da) | 1986-12-01 | 1988-06-02 | Hoffmann La Roche | Oxadiazol-, thiadiazol- og triazolforbindelser |
| JP2751309B2 (ja) | 1988-02-16 | 1998-05-18 | 三菱化学株式会社 | ピラゾール類およびこれを有効成分とする殺虫、殺ダニ、殺菌剤 |
| JPH05255268A (ja) | 1992-03-17 | 1993-10-05 | Mitsubishi Kasei Corp | ピラゾールカルボキサミド類、これを有効成分とする殺虫、殺ダニ剤および農園芸用殺菌剤 |
| TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| JP3488890B2 (ja) | 1993-11-09 | 2004-01-19 | アグロカネショウ株式会社 | ３−ｎ−置換キナゾリノン誘導体、その製造法および該化合物を含有する除草剤 |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| MXPA00006605A (es) | 1999-07-02 | 2004-12-09 | Pfizer | Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos. |
| FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
| AU2002352444A1 (en) | 2001-12-20 | 2003-07-09 | Celltech R And D Limited | Quinazolinedione derivatives |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| BRPI0418074B8 (pt) | 2003-12-25 | 2021-05-25 | Nippon Shinyaku Co Ltd | derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos |
| CA2565599C (en) | 2004-05-18 | 2012-07-31 | Schering Corporation | Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors |
| JPWO2006038741A1 (ja) | 2004-10-08 | 2008-05-15 | 萬有製薬株式会社 | チオエーテル化合物の製造方法 |
| CA2637620A1 (en) * | 2006-02-16 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| US20080255161A1 (en) | 2007-04-11 | 2008-10-16 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| FR2921926B1 (fr) | 2007-10-03 | 2009-12-04 | Sanofi Aventis | Derives de quinazolinedione,leur preparation et leurs applications therapeutiques. |
| CA2710118A1 (en) | 2007-12-20 | 2009-07-02 | Cellzome Limited | Sulfamides as zap-70 inhibitors |
| MX2010010272A (es) | 2008-03-19 | 2011-05-25 | Chembridge Corp | Nuevos inhibidores de tirosina quinasa. |
| AR071392A1 (es) | 2008-04-23 | 2010-06-16 | Takeda Pharmaceutical | Derivados de iminopiridina y su uso |
| TW201006823A (en) | 2008-07-14 | 2010-02-16 | Novartis Ag | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis |
| WO2010056230A1 (en) | 2008-10-15 | 2010-05-20 | Cv Therapeutics, Inc. | 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors |
| US20100160369A1 (en) | 2008-12-04 | 2010-06-24 | Exelixis, Inc. | S1P1 Agonists and Methods of Making And Using |
| JP5948246B2 (ja) * | 2009-10-23 | 2016-07-06 | ノバルティス アーゲー | Ｂｃｒ−ａｂｌ、ｃ−ｋｉｔ、ｄｄｒ１、ｄｄｒ２またはｐｄｇｆ−ｒのキナーゼ活性によって仲介される増殖性障害およびその他の病態の治療方法 |
| JO3634B1 (ar) * | 2009-11-17 | 2020-08-27 | Novartis Ag | طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r |
| US8765773B2 (en) | 2010-10-18 | 2014-07-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2012061926A1 (en) | 2010-11-08 | 2012-05-18 | Zalicus Pharmaceuticals Ltd. | Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers |
| CA2829123C (en) | 2011-03-14 | 2016-04-12 | Eternity Bioscience Inc. | Quinazolinediones and their use |
| TWI527800B (zh) | 2011-04-01 | 2016-04-01 | 南京英派藥業有限公司 | 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用 |
| EP2773623B1 (en) | 2011-11-01 | 2020-04-29 | Impact Therapeutics, Inc. | 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof |
| CA2871237A1 (en) | 2012-04-24 | 2013-10-31 | Chugai Seiyaku Kabushiki Kaisha | Benzamide derivative |
-
2013
- 2013-04-24 AR ARP130101381A patent/AR090835A1/es unknown
- 2013-04-24 RU RU2014146993A patent/RU2014146993A/ru unknown
- 2013-04-24 SG SG11201406860SA patent/SG11201406860SA/en unknown
- 2013-04-24 US US14/396,498 patent/US9567304B2/en not_active Expired - Fee Related
- 2013-04-24 EP EP13781062.8A patent/EP2842946B1/en not_active Not-in-force
- 2013-04-24 BR BR112014026305A patent/BR112014026305A2/pt not_active Application Discontinuation
- 2013-04-24 JP JP2014512633A patent/JP6130828B2/ja active Active
- 2013-04-24 CA CA2871453A patent/CA2871453A1/en not_active Abandoned
- 2013-04-24 MX MX2014012992A patent/MX2014012992A/es unknown
- 2013-04-24 AU AU2013253541A patent/AU2013253541A1/en not_active Withdrawn
- 2013-04-24 CN CN201380033226.5A patent/CN104379568A/zh active Pending
- 2013-04-24 HK HK15104398.3A patent/HK1203943A1/xx unknown
- 2013-04-24 KR KR20147032551A patent/KR20150003849A/ko not_active Withdrawn
- 2013-04-24 WO PCT/JP2013/062006 patent/WO2013161853A1/ja not_active Ceased
- 2013-04-24 TW TW102114529A patent/TW201348213A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013253541A1 (en) | 2014-11-20 |
| EP2842946A4 (en) | 2015-09-09 |
| JPWO2013161853A1 (ja) | 2015-12-24 |
| SG11201406860SA (en) | 2014-11-27 |
| WO2013161853A1 (ja) | 2013-10-31 |
| US9567304B2 (en) | 2017-02-14 |
| MX2014012992A (es) | 2015-08-14 |
| EP2842946A1 (en) | 2015-03-04 |
| CA2871453A1 (en) | 2013-10-31 |
| TW201348213A (zh) | 2013-12-01 |
| CN104379568A (zh) | 2015-02-25 |
| JP6130828B2 (ja) | 2017-05-17 |
| US20150141400A1 (en) | 2015-05-21 |
| HK1203943A1 (en) | 2015-11-06 |
| BR112014026305A2 (pt) | 2017-06-27 |
| RU2014146993A (ru) | 2016-06-10 |
| EP2842946B1 (en) | 2016-09-28 |
| KR20150003849A (ko) | 2015-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090835A1 (es) | Derivados de quinazolindiona | |
| AR090836A1 (es) | Derivados de benzamida | |
| AR119657A1 (es) | Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos | |
| AR112290A1 (es) | Dinucleótidos cíclicos como agentes anticáncer | |
| AR100059A1 (es) | Compuestos útiles como inmunomoduladores | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR121044A1 (es) | Inhibidores de egfr | |
| AR106138A1 (es) | Compuestos y métodos para inhibir jak | |
| AR115885A1 (es) | Compuestos derivados de 1h-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y su uso en combinación con un agente de inmunoterapia anticancerígeno | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR119018A1 (es) | Inhibidores de proteína quinasas dependientes de adn | |
| AR088565A1 (es) | Inhibidor de cetp de oxazolidinona biciclico fusionado | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR105648A1 (es) | Métodos para la preparación de ácidos biliares y derivados de los mismos | |
| AR094346A1 (es) | Derivados de azaindol como inhibidores de las proteína quinasas | |
| AR088748A1 (es) | Macrociclos como inhibidores del factor xia | |
| AR095077A1 (es) | Lípidos y composiciones lípidas para la entrega de agentes activos | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR093818A1 (es) | Compuesto de 1-(bencil sustituido)piperazina sustituida | |
| AR095781A1 (es) | Inhibidores de proteínas de quinasa | |
| AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
| AR086817A1 (es) | Compuestos inhibidores de la fosfodiesterasa tipo 10a | |
| AR114369A1 (es) | Dinucleótidos cíclicos como agentes antineoplásicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |